<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width,initial-scale=1.0">
    <link href="style/css/main.css" rel="stylesheet">
    <script src="//ajax.googleapis.com/ajax/libs/jquery/3.1.1/jquery.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/popper.js/1.9.4/umd/popper.min.js"></script>
    <script src="js/vendor/bootstrap.min.js"></script>
    <script src="js/front-end/stickyHeader.js"></script>
    <script src="js/front-end/searchToggle.js"></script>
    <script src="js/front-end/notifyMainToggle.js"></script>
    <script src="js/front-end/notifyTray.js"></script>
    <script src="js/front-end/headerMainNavMainToggle.js"></script>
    <script src="js/front-end/navMainSubToggleMobile.js"></script>
    <script src="js/front-end/swapBackground.js"></script>
    <script src="js/front-end/navMainSubColumns.js"></script>
    <script src="js/front-end/tabs.js"></script>
    <script src="js/front-end/internalLinkScrollEffect.js"></script>
    <script src="https://use.fontawesome.com/3942864d90.js"></script>
    <title>First Line Data</title>
  </head>
  <body>
    <form>
      <div class="pageWrap">
        <div class="notifyMain">
          <div class="notifyMain-inner">
            <div class="notifyMain-content">
              <h2 class="notifyMain-heading">Indication and Limitation of use</h2>
              <div class="notifyMain-copy">
                <p>Vectibix® is indicated for the treatment of patients with wild‑type RAS metastatic colorectal cancer (mCRC). Wild‑type RAS is defined as wild‑type in both KRAS and NRAS as determined by an FDA‑approved test for this use: </p>
                <ul>
                  <li>As first‑line therapy in combination with FOLFOX  </li>
                  <li>As monotherapy following disease progression after prior treatment with fluoropyrimidine‑, oxaliplatin‑, an  irinotecan‑containing chemotherapy </li>
                </ul>
                <p>Limitation of Use: Vectibix<sup>&reg;</sup>is not indicated for the treatment of patients with RAS‑mutant mCRC or for whom RAS mutation status is unknown.  </p>
              </div>
            </div>
            <div class="notifyMain-close"></div>
          </div>
        </div>
        <div id="pageTop"></div>
        <header class="headerMain">
          <div class="headerMain-util">
            <div class="headerMain-utilInner">
              <ul class="headerMain-navUtil">
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="">Link Number One</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="">Link Number Two</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="">Link Number Three</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="">Link Number Four</a></li>
                <li class="headerMain-navUtilItem"><a class="headerMain-navUtilLink" href="">Link Number Five</a></li>
              </ul>
              <div class="headerMain-utilCollateral"><a class="headerMain-ctaBtn" href="">Visit Patient Site</a>
                <div class="headerMain-search">
                  <label for="headerMainSearch"></label>
                  <input class="headerMain-searchBox" type="text" placeholder="Search" id="headerMainSearch"><span class="headerMain-searchToggle"></span>
                </div>
              </div>
              <ul class="headerMain-navUtilMobile">
                <li class="headerMain-navUtilMobileItem"><a class="headerMain-navUtilMobileLink" href="">Link Number One</a></li>
                <li class="headerMain-navUtilMobileItem"><a class="headerMain-navUtilMobileLink" href="">Link Number Two</a></li>
                <li class="headerMain-navUtilMobileItem"><a class="headerMain-navUtilMobileLink" href="">Link Number Three</a></li>
              </ul>
            </div>
          </div>
          <div class="headerMain-main">
            <div class="headerMain-mainInner">
              <div class="headerMain-logo"><a class="headerMain-logoLink" href=""><img class="headerMain-logoImg" src="img/content-images/logo-main.png"></a></div>
              <ul class="headerMain-navMain">
                <li class="headerMain-navMainItem is-current"><a class="headerMain-navMainLink" href=""> <em class="px-1">RAS </em>Story</a>
                  <div class="headerMain-subContent">
                    <div class="headerMain-subContentInner">
                      <ul class="headerMain-subNav">
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href=""> <em class="px-1">KRAS </em>and<em class="px-1">NRAS </em></a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">WT <em class="px-1">RAS </em>in PRIME</a></li>
                      </ul>
                      <div class="headerMain-subcollateral"><a class="headerMain-subcollateralCta" href="">See efficacy in WT RAS mCRC patients from PRIME</a></div>
                    </div>
                  </div>
                </li>
                <li class="headerMain-navMainItem"><a class="headerMain-navMainLink" href="">First-line data</a>
                  <div class="headerMain-subContent">
                    <div class="headerMain-subContentInner">
                      <ul class="headerMain-subNav">
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">Study design</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">Progression-free survival</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">Objective response rate</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">Overall survival</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">Prime safety Profile</a></li>
                      </ul>
                      <div class="headerMain-subcollateral"><a class="headerMain-subcollateralCta" href="">Learn how WT <em>RAS</em>mCRC patients were identified in PRIME</a></div>
                    </div>
                  </div>
                </li>
                <li class="headerMain-navMainItem"><a class="headerMain-navMainLink" href="">Third-line data</a>
                  <div class="headerMain-subContent">
                    <div class="headerMain-subContentInner">
                      <ul class="headerMain-subNav">
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">0007 Study</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">ASPECCT Study</a></li>
                      </ul>
                      <div class="headerMain-subcollateral"><a class="headerMain-subcollateralCta" href="">What clinical characteristics affect your third-line treatment decision?</a></div>
                    </div>
                  </div>
                </li>
                <li class="headerMain-navMainItem"><a class="headerMain-navMainLink" href="">Administration</a></li>
                <li class="headerMain-navMainItem"><a class="headerMain-navMainLink" href="">Patient Profiles</a>
                  <div class="headerMain-subContent">
                    <div class="headerMain-subContentInner">
                      <ul class="headerMain-subNav">
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">First-line: Roy</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">First-line: Brian</a></li>
                        <li class="headerMain-subNavItem"><a class="headerMain-subMainLink" href="">First-line: Connie</a></li>
                      </ul>
                      <div class="headerMain-subcollateral"><a class="headerMain-subcollateralCta" href="">Learn how WT <em>RAS</em>mCRC patients were identified in PRIME</a></div>
                    </div>
                  </div>
                </li>
                <li class="headerMain-navMainItem"><a class="headerMain-navMainLink" href="">Access</a></li>
              </ul>
              <div class="headerMain-navMainToggle">
                <div class="headerMain-navMainToggleLine"></div>
                <div class="headerMain-navMainToggleLine"></div>
                <div class="headerMain-navMainToggleLine"></div>
              </div>
            </div>
          </div>
        </header>
        <main>
          <div class="hero" style="background-image:url(img/content-images/hero.png);">
            <div class="hero-inner">
              <div class="hero-copy"><span class="hero-zone1">In the first-line treatment of patients with WT<em class="px-1">RAS</em><sup>&reg;</sup>mCRC<sup>1 </sup></span><span class="hero-zone2">Vectibix<sup>&reg;</sup>: The first and only anti-EGFR approved in combination with FOLFOX <sup>1</sup></span></div>
            </div>
          </div>
          <section class="py-12">
            <div class="container">
              <h1 class="colorBrandBlue mb-5">PRIME: a predefined retrospective subset analysis of a phase 3, open-label, randomized (1:1), multicenter study of Vectibix<sup>&reg;</sup> Q2W + FOLFOX vs FOLFOX Q2W alone in first-line patients<sup>1,2</sup></h1>
              <figure class="mb-5"><img class="d-md-none" src="img/content-images/first-line-chart-1-sm.svg"><img class="d-none d-md-block" src="img/content-images/first-line-chart-1-lg.svg"></figure>
              <ul class="textLg colorGrayDark">
                <li>Primary endpoint was PFS<sup>2</sup></li>
                <li>Key secondary endpoints were OS, ORR,<sup>§</sup> and safety<sup>2</sup></li>
              </ul>
              <p class="pullFirstChar mb-0 colorGrayDark">*Defined as wild type in both <em>KRAS </em>and <em>NRAS.</em><sup>1</sup></p>
              <p class="pullFirstChar mb-0 colorGrayDark"><sup>&dagger;</sup>Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="pullFirstChar mb-0 colorGrayDark"><sup>&Dagger;</sup><em>RAS mutation status was determined for 620 patients using Sanger bidirectional sequencing and Surveyor</em><sup>&reg;</sup>/WAVE<sup>&reg;</sup>analysis.<sup>1</sup></p>
              <p class="pullFirstChar colorGrayDark mb-0"><sup>§</sup>Objective tumor response was evaluated by blinded central radiology review using modified RECIST criteria.<sup>2</sup></p>
              <p class="colorGrayDark">ECOG PS = Eastern Cooperative Oncology Group Performance Status; EGFR = epidermal growth factor receptor; mCRC = metastatic colorectal cancer; MT = mutant type; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; Q2W = every 2 weeks; RECIST = Response Evaluation Criteria in Solid Tumors; WT = wild type.</p>
              <h2 class="colorBrandBlue mb-5">Patient demographics and clinical characteristics<sup>1</sup></h2>
              <div class="row">
                <div class="col-md-9">
                  <table class="table--fiesta" width="100%">
                    <thead>
                      <tr>
                        <th>Demographic or clinical characteristic	</th>
                        <th>WT* KRAS mCRC	</th>
                        <th>WT RAS<sup>&dagger;</sup>mCRC</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <th>Male </th>
                        <td>64%</td>
                        <td>65% </td>
                      </tr>
                      <tr>
                        <th>Race
                          <ul class="list-unstyled normalWeight pl-md-4 mb-0">
                            <li>White</li>
                            <li>Black</li>
                            <li>Hispanic or Latino </li>
                          </ul>
                        </th>
                        <td>
                          <ul class="list-unstyled pt-5 mb-0">
                            <li>92%</li>
                            <li>2%</li>
                            <li>4%</li>
                          </ul>
                        </td>
                        <td> 
                          <ul class="list-unstyled pt-5 mb-0">
                            <li>91%</li>
                            <li>2%</li>
                            <li>5%</li>
                          </ul>
                        </td>
                      </tr>
                      <tr>
                        <th>Colon Cancer </th>
                        <td>66% </td>
                        <td>65%</td>
                      </tr>
                      <tr>
                        <th>Rectal Cancer </th>
                        <td>34%</td>
                        <td>35%</td>
                      </tr>
                      <tr>
                        <th>ECOG PS 
                          <ul class="list-unstyled normalWeight pl-md-4 mb-0">
                            <li>0</li>
                            <li>1</li>
                            <li>2 </li>
                          </ul>
                        </th>
                        <td>
                          <ul class="list-unstyled pt-5 mb-0">
                            <li>56%</li>
                            <li>38%</li>
                            <li>6%</li>
                          </ul>
                        </td>
                        <td>
                          <ul class="list-unstyled pt-5 mb-0">
                            <li>57%</li>
                            <li>37%</li>
                            <li>6%</li>
                          </ul>
                        </td>
                      </tr>
                      <tr>
                        <th>Median Age, Years </th>
                        <td>61.5</td>
                        <td>61</td>
                      </tr>
                    </tbody>
                  </table>
                </div>
                <div class="col-md-3">
                  <div class="row">
                    <div class="col-12">
                      <p class="h2 colorBrandBlue mb-5 mb-md-7">In patients with WT <em class="px-1">KRAS</em>mCRC <sup>2</sup></p>
                    </div>
                    <div class="col-12 col-sm-4 col-md-12 mb-2 mb-sm-7">
                      <p class="h2 colorBrandOrange">86% had liver metastases<sup>2</sup></p>
                    </div>
                    <div class="col-12 col-sm-4 col-md-12 mb-2 mb-sm-7">
                      <p class="h2 colorBrandOrange">18% had liver-limited metastases<sup>2</sup></p>
                    </div>
                    <div class="col-12 col-sm-4 col-md-12 mb-2 mb-sm-7">
                      <p class="h2 colorBrandOrange">79% had 2 or more metastatic sites<sup>2</sup></p>
                    </div>
                  </div>
                </div>
              </div>
              <p class="pullFirstChar mb-0 colorGrayDark">*Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="pullFirstChar mb-0 colorGrayDark"><sup>&dagger;</sup>Defined as wild type in both <em>KRAS </em>and <em>NRAS.</em><sup>1</sup></p>
              <p class="colorGrayDark">ECOG PS = Eastern Cooperative Oncology Group Performance Status; mCRC = metastatic colorectal cancer; WT = wild type.</p>
            </div>
          </section>
          <section class="py-12 fillGradientBlue">
            <div class="container">
              <div class="row">
                <div class="col-md-9">
                  <p class="colorBrandOrangeLight textLg">In the PRIME study of Vectibix® + FOLFOX vs FOLFOX alone<sup>1 </sup></p>
                  <h2 class="fontDefault h1">27.8% improvement in median PFS with Vectibix<sup>&reg;</sup>+ FOLFOX<sup>1</sup></h2>
                  <hr class="hr--fade">
                  <p class="textLg mb-0">Significant increase in median PFS with Vectibix<sup>&reg;</sup>+ FOLFOX in patients with WT<em class="px-1">KRAS*</em>mCRC (n=325)<sup>1</sup>:</p>
                  <ul class="textLg mb-7">
                    <li>PFS (prespecified major efficacy endpoint): 9.6 months vs 8.0 months with FOLFOX alone (n = 331) (HR = 0.80, 95% CI: 0.66–0.97; P = 0.02)<sup>1</sup></li>
                  </ul>
                  <h3 class="h2 mb-5">Retrospective exploratory analysis in the WT RAS<sup>&dagger;</sup>subgroup in PRIME<sup>1</sup></h3>
                </div>
              </div>
              <figure class="mb-5"><img class="d-md-none" src="img/content-images/pfs-table-sm.png"><img class="d-none d-md-block" src="img/content-images/pfs-table-lg.png"></figure>
              <ul class="mb-5 textLg">
                <li>There were no OS or PFS benefits in patients treated with Vectibix<sup>&reg;</sup>with RAS-mutant mCRC<sup>1</sup></li>
              </ul>
              <p class="textLg pullFirstChar mb-0">*Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="textLg pullFirstChar mb-0"> <sup>&dagger;</sup>Defined as wild type in both <em>KRAS </em>and <em>NRAS.</em><sup>1</sup></p>
              <p class="textLg">CI = confidence interval; HR = hazard ratio; mCRC = metastatic colorectal cancer; PFS = progression-free survival; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; WT = wild type.</p>
            </div>
          </section>
          <section class="py-12">
            <div class="container">
              <div class="row">
                <div class="col-md-9">
                  <p class="colorBrandBlue textLg">In the PRIME study of Vectibix<sup>&reg;</sup>+ FOLFOX vs FOLFOX alone<sup>1 </sup></p>
                  <h2 class="colorBrandOrange fontDefault h1">Vectibix<sup>&reg; </sup>+ FOLFOX improved ORR1*</h2>
                  <hr class="hr--fade colorBrandBlue">
                  <p class="textLg mb-0">
                     In patients with WT <em>KRAS</em><sup class="px-1">&dagger;</sup> mCRC, Vectibix<sup>&reg;</sup> + FOLFOX (n = 325) demonstrated<sup>1</sup>:</p>
                  <ul class="textLg mb-7">
                    <li>ORR: 54% (95% CI: 48%–59%) vs 47% (95% CI: 41%–52%) with FOLFOX alone (n = 331)<sup>1</sup></li>
                  </ul>
                  <h3 class="h2 mb-5 colorBrandBlue">ORR in patients with WT <em>RAS</em><sup class="px-1">‡</sup> mCRC in the PRIME study<sup>1</sup></h3>
                </div>
              </div>
              <figure class="mb-5"><img class="d-md-none" src="img/content-images/first-line-chart-3-sm.svg"><img class="d-none d-md-block" src="img/content-images/first-line-chart-3-lg.svg"></figure>
              <p class="pullFirstChar mb-0">*Objective tumor response was evaluated by blinded central radiology review using modified RECIST criteria.<sup>2</sup></p>
              <p class="pullFirstChar mb-0"> <sup>&dagger;</sup>Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="pullFirstChar mb-0"> <sup>&Dagger;</sup>Defined as wild type in both KRAS and NRAS.<sup>1</sup></p>
              <p>CI = confidence interval; mCRC = metastatic colorectal cancer; ORR = objective response rate; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; RECIST = Response Evaluation Criteria in Solid Tumors; WT = wild type.</p>
            </div>
          </section>
          <section class="py-12 fillGradientBlue">
            <div class="container">
              <p class="colorBrandOrangeLight textLg">In a retrospective exploratory analysis of OS in the PRIME study of Vectibix<sup>&reg;</sup>+ FOLFOX vs FOLFOX alone<sup>1 </sup></p>
              <h2 class="fontDefault h1">27.8% improvement in median PFS with Vectibix<sup>&reg;</sup>+ FOLFOX<sup>1</sup></h2>
              <hr class="hr--fade">
              <p class="textLg mb-0">In patients with WT<em>KRAS</em><sup class="px-1">&dagger;</sup>mCRC, Vectibix<sup>&reg;</sup>+ FOLFOX (n = 325) demonstrated<sup>1</sup>:</p>
              <ul class="textLg mb-7">
                <li>OS (exploratory analysis): 23.8 months vs 19.4 months with FOLFOX alone (n = 331)  (HR = 0.83, 95% CI: 0.70–0.98)<sup>1</sup></li>
              </ul>
              <h3 class="h2 mb-5">27.7% increase in median OS with Vectibix<sup>&reg;</sup> + FOLFOX vs FOLFOX alone in patients with WT <em>RAS</em><sup>&dagger;</sup> mCRC (HR = 0.77, 95% CI: 0.64–0.94)<sup>1</sup></h3>
              <figure class="mb-5"><img class="d-md-none" src="img/content-images/first-line-chart-4-sm.png"><img class="d-none d-md-block" src="img/content-images/first-line-chart-4-lg.png"></figure>
              <ul class="mb-5 textLg">
                <li>There were no OS or PFS benefits in patients treated with Vectibix<sup>&reg;</sup>with RAS-mutant mCRC<sup>1</sup></li>
              </ul>
              <p class="textLg pullFirstChar mb-0">*Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="textLg pullFirstChar mb-0"> <sup>&dagger;</sup>Defined as wild type in both <em>KRAS </em>and <em>NRAS.</em><sup>1</sup></p>
              <p class="textLg">CI = confidence interval; HR = hazard ratio; mCRC = metastatic colorectal cancer; PFS = progression-free survival; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; WT = wild type.</p>
            </div>
          </section>
          <section class="py-12">
            <div class="container">
              <p class="colorBrandBlue textLg">In patients with WT <em>RAS*</em>mCRC in the PRIME study<sup>1 </sup></p>
              <h2 class="colorBrandOrange fontDefault h1 mb-5">Similar safety profile to patients with WT <em>KRAS </em><sup>&dagger; </sup>mCRC<sup>1,3,4</sup></h2>
              <div class="d-none d-md-block">
                <ul class="tabs">
                  <li class="tabs-item is-active" data-tab="tab-1">Adverse reactions</li>
                  <li class="tabs-item" data-tab="tab-2">Chemotherapy-associated adverse reactions</li>
                </ul>
                <div class="tabs-content is-active" id="tab-1">
                  <figure class="mb-5"><img src="img/content-images/prime-safety-profile-table-lg.png"></figure>
                </div>
                <div class="tabs-content" id="tab-2">
                  <figure class="mb-5"><img src="img/content-images/prime-safety-profile-table-2-lg.png"></figure>
                </div>
              </div>
              <figure class="mb-5 d-md-none"><img src="img/content-images/prime-safety-profile-table-sm.png"></figure>
              <ul class="textLg mb-7">
                <li>ORR: 54% (95% CI: 48%–59%) vs 47% (95% CI: 41%–52%) with FOLFOX alone (n = 331)<sup>1</sup></li>
              </ul>
              <h3 class="h2 mb-5 colorBrandBlue">ORR in patients with WT <em>RAS</em><sup class="px-1">‡</sup> mCRC in the PRIME study<sup>1</sup></h3>
              <p class="pullFirstChar mb-0">*Objective tumor response was evaluated by blinded central radiology review using modified RECIST criteria.<sup>2</sup></p>
              <p class="pullFirstChar mb-0"> <sup>&dagger;</sup>Exon 2 in codons 12 or 13.<sup>1</sup></p>
              <p class="pullFirstChar mb-0"> <sup>&Dagger;</sup>Defined as wild type in both KRAS and NRAS.<sup>1</sup></p>
              <p>CI = confidence interval; mCRC = metastatic colorectal cancer; ORR = objective response rate; PRIME = Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy; RECIST = Response Evaluation Criteria in Solid Tumors; WT = wild type.</p>
            </div>
          </section>
          <div class="container">
            <div class="inlined py-16 colorGrayDark">
              <h2 class="h5">References:</h2>
              <ol>
                <li> Vectibix<sup>®</sup> (panitumumab) prescribing information, Amgen. </li>
                <li> Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 treatment and <em>RAS</em> mutations in colorectal cancer. <em>N Engl J Med.</em> 2013;369(11):1023-1034. </li>
                <li> Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Colon Cancer V2.2017. ©National Comprehensive Cancer Network, Inc 2017. All rights reserved. Accessed April 21, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.</li>
              </ol>
            </div>
            <div class="notifyTray is-sticky">
              <div class="notifyTray-inner">
                <div class="notifyTray-content">
                  <h2>IMPORTANT SAFETY INFORMATION</h2>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                  <p>Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. </p>
                </div>
                <div class="notifyTray-toggle">See More</div>
              </div>
            </div>
          </div>
        </main>
        <footer class="footerMain"><a class="footerMain-topLink" href="#pageTop">Back To Top<i class="footerMain-topLinkIcon fa-chevron-up"></i></a>
          <div class="footerMain-inner">
            <div class="footerMain-main">
              <ul class="footerMain-nav">
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Site Map</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Privacy Statement</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Terms of Use</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Amgen Oncology</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Amgen Assist 360<sup>TM</sup></a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Amgen MedInfo</a></li>
                <li class="footerMain-navItem"><a class="footerMain-navLink" href="">Advertising Choices</a></li>
              </ul>
              <div class="footerMain-logo"> <a class="footerMain-logoLink" href=""><img class="footerMain-logoImg" src="img/content-images/logo-amgen.png"></a></div>
            </div>
            <div class="footerMain-collateral">
              <p>2017 &copy; Amgen Inc. All rights reserved.</p>
              <p>This website is intended for US healthcare professionals only.</p>
            </div>
          </div>
        </footer>
      </div>
    </form>
  </body>
</html>